A pilot study of human interferon β gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes

Japanese Journal of Clinical Oncology

Volumn 38, Issue 12, 2008, Pages 849-856

  Matsumoto, Kazuhiko ^a,e   Kubo, Hitomi ^a   Murata, Hiroshi ^a   Uhara, Hisashi ^a   Takata, Minoru ^a   Shibata, Shinichi ^b   Yasue, Satoshi ^b   Sakakibara, Akihiro ^b   Tomita, Yasushi ^b   Kageshita, Toshiro ^c   Kawakami, Yutaka ^d   Mizuno, Masaaki ^b   Yoshida, Jun ^b   Saida, Toshiaki ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Clinical trial; Gene therapy; Interferon ; Malignant melanoma

Indexed keywords

BETA INTERFERON; CARMUSTINE; CATION; DACARBAZINE; HLA ANTIGEN CLASS 2; LIPOSOME; PHOSPHATE BUFFERED SALINE; PLASMID DNA; VINCRISTINE;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; ANTIGEN EXPRESSION; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VIVO STUDY; INJECTION SITE BLEEDING; INJECTION SITE INFECTION; INJECTION SITE REACTION; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; MELANOMA CELL; NONVIRAL GENE DELIVERY SYSTEM; OUTCOME ASSESSMENT; PILOT STUDY; SKIN INFLAMMATION; SKIN METASTASIS; SUBCUTANEOUS TISSUE TUMOR; TREATMENT DURATION;

EID: 57249107928     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn114     Document Type: Article

References (20)

1. Kubo H, Ashida A, Matsumoto K, Kageshita T, Yamamoto A, Saida T. Interferon-β therapy for malignant melanoma: The dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells. Arch Dermatol Res 2008;300:297-301.
2. Kageshita T, Mizuno M, Ono T, Matsumoto K, Saida T, Yoshida J. Growth inhibition of human malignant melanoma transfected with the human interferon-β gene by means of cationic liposomes. Melanoma Res 2001;11:337-42.
3. Yoshida J, Mizuno M, Fujii M, Kajita Y, Nakahara N, Hatano M, et al. Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon β gene using cationic liposomes. Hum Gene Ther 2004;15:77-86.
4. Etoh T, Thomas L, Pastel-Levy C, Colvin RB, Mihm MC, Byers HR. Role of Integrinα2β1 (VLA-2) in the migration of human melanoma cells on laminin and type IV collagen. J Invest Dermatol 1993;100:640-7.
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guideline to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
6. Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, et al. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 2003;13:521-30.
7. Ogino T, Bandoh N, Hayashi T, Miyokawa N, Harabuchi Y, Ferrone S. Association of tapasin and HLA Class I antigen downregulation in primary maxillary sinus squamous cell carcinoma lesions with patients' reduced survival. Clin Cancer Res 2003;9:4043-51.
8. Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, Ferrone S. Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods 1993;161: 239-56.
9. Fountain JW, Karayiorgou M, Emstoff MS, Kirkwood JM, Vlock DR, Titus-Emstoff L, et al. Homozygous deletion within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 1992;89:10557-61.
10. Hanson C, Kopf I, Weijdegar B, Weimarck A, Stiemer U. Sensitivity to extrinsically supplied interferon and the endogenous expression of interferon in melanoma cell lines. Melanoma Res 1999;9:451-6.
11. Nagatani T, Okazawa H, Kambara T, Satoh K, Nishiyama T, Tokura H, et al. Effect of natural interferon-β on the growth of melanoma cell lines. Melanoma Res 1998;8:295-9.
12. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta Ia in healthy volunteers. J Interferon Cytokine Res 2000;20:857-66.
13. Parmiani G, Colombo MP. Somatic gene therapy of human melanoma: preclinical studies and early clinical trials. Melanoma Res 1995;5: 295-301.
14. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang Z-Y, Aruga A, et al. Immune response in human melanoma after transfer of an allogenic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl 1cad Sci USA 1996;93: 15388-93.
15. Yoshida J, Mizuno M, Wakabayashi T. Interferon-β gene therapy for cancer: Basic research to clinical application. Cancer Sci 2004;95: 858-65.
16. + T cells. Proc Natl Acad Sci 1994;91:2890-4.
17. Hashimoto K, Higashiyama S, Asada H, Hashimura E, Kobayashi T. Sudo K. et al. Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem 1994;269:20060-6.
18. Ryuke Y, Mizuno M, Natsume A, Suzuki O, Nobayashi M, Kageshita T, et al. Growth inhibition of natural killer cells by liposome-mediated interferon-β gene therapy. Melanoma Res 2003;13:349-56.
19. Seliger B, Maeurer MJ, Ferrone S. TAP off - tumors on. Immunol Today 1997;18:292-9.
20. Nobayashi M, Mizuno M, Kageshita T, Matsumoto K, Saida T, Yoshida J. Repeated cationic multilamellar liposome-mediated gene transfer enhanced transduction efficiency against murine melanoma cell lines. J Dermatol Sci 2002;29:206-13.